HomeAI · summaries
Storia in 2 fonti
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval - Artivion (NYSE:AORT)
Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aortic dissection patients.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
- ·
benzinga.com
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval - Artivion (NYSE:AORT)
Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aortic dissection patients.